Adi Kartolo

607 total citations
29 papers, 385 citations indexed

About

Adi Kartolo is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Adi Kartolo has authored 29 papers receiving a total of 385 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 8 papers in Immunology. Recurrent topics in Adi Kartolo's work include Cancer Immunotherapy and Biomarkers (22 papers), CAR-T cell therapy research (5 papers) and Melanoma and MAPK Pathways (5 papers). Adi Kartolo is often cited by papers focused on Cancer Immunotherapy and Biomarkers (22 papers), CAR-T cell therapy research (5 papers) and Melanoma and MAPK Pathways (5 papers). Adi Kartolo collaborates with scholars based in Canada and Spain. Adi Kartolo's co-authors include Tara Baetz, Wilma M. Hopman, Cynthia Yeung, Andrew Robinson, Teresa M. Petrella, Sidra Khalid, Andrea S. Fung, Harriet Feilotter, John Lenehan and Bishal Gyawali and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Nature Reviews Clinical Oncology.

In The Last Decade

Adi Kartolo

26 papers receiving 385 citations

Peers

Adi Kartolo
Maike Trommer Germany
Yukinori Ozaki Japan
Catherine Vézina Canada
Arun K. Singavi United States
Arissa Young United States
Idoia Morilla Spain
Richard Mansour United States
Mi Hwa Heo South Korea
Sara Alcántara Luna Spain
Hirotsugu Ariizumi Japan
Maike Trommer Germany
Adi Kartolo
Citations per year, relative to Adi Kartolo Adi Kartolo (= 1×) peers Maike Trommer

Countries citing papers authored by Adi Kartolo

Since Specialization
Citations

This map shows the geographic impact of Adi Kartolo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adi Kartolo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adi Kartolo more than expected).

Fields of papers citing papers by Adi Kartolo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adi Kartolo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adi Kartolo. The network helps show where Adi Kartolo may publish in the future.

Co-authorship network of co-authors of Adi Kartolo

This figure shows the co-authorship network connecting the top 25 collaborators of Adi Kartolo. A scholar is included among the top collaborators of Adi Kartolo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adi Kartolo. Adi Kartolo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Chan, Sze Wah Samuel, Jack Young, Do-Hoon Kim, et al.. (2024). Concurrent immunotherapy and radiation in cisplatin-ineligible patients with HNSCC: a systematic review & meta-analysis. Immunotherapy. 16(20-22). 1227–1233. 2 indexed citations
4.
Yeung, Cynthia, et al.. (2023). Association of Circadian Timing of Initial Infusions of Immune Checkpoint Inhibitors with Survival in Advanced Melanoma. Immunotherapy. 15(11). 819–826. 16 indexed citations
5.
Kartolo, Adi, Wilma M. Hopman, Linda Liu, et al.. (2022). Real-World Evidence of Systemic Therapy Sequencing on Overall Survival for Patients with Metastatic BRAF-Mutated Cutaneous Melanoma. Current Oncology. 29(3). 1501–1513. 1 indexed citations
6.
Kartolo, Adi & Bishal Gyawali. (2022). Should the control arms of randomized trials have an expiry date?. Nature Reviews Clinical Oncology. 19(7). 425–426. 6 indexed citations
7.
Kartolo, Adi, et al.. (2022). Long-Term Toxicities of Immune Checkpoint Inhibitor (ICI) in Melanoma Patients. Current Oncology. 29(10). 7953–7963. 20 indexed citations
8.
Kartolo, Adi, et al.. (2022). Complete Response and Survival Outcomes in Patients with Advanced Cancer on Immune Checkpoint Inhibitors. Immunotherapy. 14(10). 777–787. 3 indexed citations
9.
Kartolo, Adi, et al.. (2021). Consolidative durvalumab outcomes in stage III non-small cell lung cancer in a multi-centre study. Cancer Treatment and Research Communications. 29. 100496–100496. 12 indexed citations
10.
11.
Yeung, Cynthia, et al.. (2021). Safety and Clinical Outcomes of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Diseases. Journal of Immunotherapy. 44(9). 362–370. 19 indexed citations
12.
Kartolo, Adi, Harriet Feilotter, Wilma M. Hopman, Andrea S. Fung, & Andrew Robinson. (2021). A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors. Cancer Treatment and Research Communications. 27. 100330–100330. 25 indexed citations
13.
Kartolo, Adi, Tanveer Towheed, & Mihaela Mates. (2021). A Case of Successful Pembrolizumab Rechallenge in a Patient with Non-Small-Cell Lung Cancer and Grade 3 Dermatomyositis. Immunotherapy. 13(6). 477–481. 4 indexed citations
14.
Kartolo, Adi, et al.. (2021). Impact of Baseline Corticosteroids on Immunotherapy Efficacy in Patients With Advanced Melanoma. Journal of Immunotherapy. 44(4). 167–174. 15 indexed citations
15.
Kartolo, Adi, et al.. (2020). Serum Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Prognosticating Immunotherapy Efficacy. Immunotherapy. 12(11). 785–798. 27 indexed citations
16.
Kartolo, Adi, et al.. (2020). Prognosticating Role of Serum Eosinophils on Immunotherapy Efficacy in Patients with Advanced Melanoma. Immunotherapy. 13(3). 217–225. 8 indexed citations
17.
Kartolo, Adi, et al.. (2018). The efficacy and toxicity of immune checkpoint inhibitors in a real-world older patient population. Journal of Geriatric Oncology. 10(3). 411–414. 55 indexed citations
18.
Kartolo, Adi, et al.. (2018). Predictors of Immunotherapy-Induced Immune-Related Adverse Events. Current Oncology. 25(5). 403–410. 89 indexed citations
19.
Kartolo, Adi, et al.. (2015). Motivation and preferences of exercise programmes in patients with inoperable metastatic lung cancer: a need assessment. Supportive Care in Cancer. 24(1). 129–137. 23 indexed citations
20.
Brown, Kaitlyn, et al.. (2012). Case Based Learning Teaching Methodology in Undergraduate Health Sciences. uO Research (University of Ottawa). 2(2). 48–48. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Maike Trommer Breakdown of academic impact, for papers by Yukinori Ozaki Breakdown of academic impact, for papers by Catherine Vézina Breakdown of academic impact, for papers by Arun K. Singavi Breakdown of academic impact, for papers by Arissa Young Breakdown of academic impact, for papers by Idoia Morilla Breakdown of academic impact, for papers by Richard Mansour Breakdown of academic impact, for papers by Mi Hwa Heo Breakdown of academic impact, for papers by Sara Alcántara Luna Breakdown of academic impact, for papers by Hirotsugu Ariizumi
Rankless by CCL
2026